A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.